Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Dengue Fever
Interventions: rDEN1delta30, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity or Overweight
Interventions: Lenbelintide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 41
States / cities: Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 38 more

Conditions: Childhood Neoplasm
Interventions: Modification in acquisition protocol, F-18 Fluorodeoxyglucose; Other · Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 9 Months to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mental Health Issue
Interventions: Expressive Helping, Caregiving Fact writing; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV
Interventions: Risk Reduction Intervention; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 13 Years to 18 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Anorexia Nervosa
Interventions: SilverCloud Health Mobile Intervention, Social Networking Intervention: Facebook; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • St Louis, Missouri • New York, New York

Conditions: Solid Tumor, MET Alteration
Interventions: VERT-002; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee

Conditions: Sleep, Mood, Caffeine Withdrawal, Anxiety, Productivity
Interventions: Clevr Sleeptime, Clevr Matcha, Clevr Chai; Other
Lead sponsor: Clevr Blends; Industry
Eligibility: 28 Years to 42 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Obstructive Sleep Apnea of Adult, Pregnancy Related
Interventions: Mandibular advancement Device; Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cerebral Palsy
Interventions: HABIT-ILE; Other
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 5 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New York, New York • Portland, Oregon

Conditions: Healthy
Interventions: Blood Collection and autologous re-infusion; Other
Lead sponsor: Bloodworks; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Prevention
Interventions: DuoGel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Tumors
Interventions: Definity Contrast; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Asthma, Obesity
Interventions: Roflumilast 500 Mcg Oral Tablet, Placebo oral capsule; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Tucson, Arizona • Chicago, Illinois + 3 more

Conditions: Healthy
Interventions: tenofovir, emtricitabine, atazanavir, ritonavir; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pregnancy
Interventions: pharmacist nicotine cessation counseling using SCRIPT protocol; Behavioral
Lead sponsor: Providence Medical Research Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab Herold Regimen, Placebo, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 8 Years to 35 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 42
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more

Conditions: Gastrectomy, Atrial Fibrillation
Interventions: A mobile health platform; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • Rochester, Minnesota

Conditions: Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma
Interventions: Botensilimab, Balstilimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injury
Interventions: Respiratory Muscle Training; Behavioral
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Stroke
Interventions: Anodal or Cathodal tDCS, Sham, Computerized naming therapy; Device · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insufficient Breast Milk Syndrome
Interventions: Breast Pump suction pattern; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
Interventions: Ranibizumab, No Ranibizumab; Drug · Other
Lead sponsor: California Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Posttraumatic Stress Disorder
Interventions: 1-Session Exposure Therapy, 3-Session Exposure Therapy; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Biokinetics Study for F-18 FDG in Pediatric Molecular Imaging

Chinese American Family Caregiver Writing Study

Project TEACH-Kenya

Helping HAND: Healing Anorexia Nervosa Digitally

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

A Single-Arm, Virtual Clinical Trial to Evaluate the Effects of a Sleep Supporting Beverage and Two Coffee Substitute Products

Mandibular Advancement Device (MAD) in Pregnant Women With Obstructive Sleep Apnea (OSA)

The Impact of Dosing Parameters on Motor Skill Acquisition and Retention in Bilateral Cerebral Palsy (BCP)

Assessment of Whole Blood Cold Stored Platelets

ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study

Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions

Trial of Roflumilast in Asthma Management (TRIM)

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Evaluation of the Effectiveness of Pharmacists in Implementing the SCRIPT Protocol

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Post-Market Surveillance With a Novel mHealth Platform

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Respiratory Motor Control and Blood Pressure Regulation After Spinal Cord Injury

Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment

Comparison of Breast Pump Suction Patterns

Analysis of Aqueous and Vitreous Humor

Optimal Dose of Early Intervention to Prevent PTSD